Haldol Decanoate (Haloperidol Decanoate)

Haloperidol decanoate is indicated for the treatment of several psychotic conditions where a long‑acting injectable formulation offers advantages in adherence, stability, and reduced relapse risk.

• Schizophrenia maintenance therapy in adults.
• Acute psychotic episodes requiring rapid symptom control.
• Chronic psychosis where oral adherence is problematic.
• Adjunctive treatment for patients stabilized on oral antipsychotics.
• Long‑term management of recurrent psychotic relapses.
• Prevention of hospitalization due to psychotic decompensation.
• Suitable for patients preferring monthly or quarterly dosing intervals.

Side effects of haloperidol decanoate vary in frequency and severity, reflecting its dopamine antagonism and depot delivery.

Common

• Sedation or drowsiness, especially during the first weeks after injection.
• Extrapyramidal symptoms such as tremor, muscle rigidity, akathisia, or mild parkinsonism.
• Anticholinergic effects including dry mouth, constipation, and blurred vision.
• Metabolic changes like modest weight gain, increased appetite, or elevated cholesterol levels.
• Orthostatic hypotension, causing dizziness or light‑headedness when standing quickly.

Serious

• Neuroleptic malignant syndrome, a rare but potentially fatal reaction marked by high fever, muscle rigidity, autonomic instability, and altered mental status.
• Tardive dyskinesia, a potentially irreversible movement disorder presenting as repetitive, involuntary facial or limb movements after prolonged exposure.

When prescribing haloperidol decanoate, clinicians should evaluate patient history and monitor for conditions that may increase risk of adverse outcomes.

• Assess for cardiovascular disease, as the drug may cause orthostatic hypotension or QT prolongation.
• Use caution in patients with a history of seizures or other neurologic disorders.
• Evaluate liver function before initiating therapy, since hepatic impairment can affect drug metabolism.
• Monitor for signs of neuroleptic malignant syndrome, especially during dose escalation.
• Screen for movement disorders, including tardive dyskinesia, during long‑term treatment.
• Discuss pregnancy and lactation status; safety data are limited, and risks are unknown.

Haloperidol decanoate can interact with other medications, influencing its efficacy or increasing the likelihood of side effects.

Avoid

• Concurrent use with other strong dopamine antagonists or high‑potency antipsychotics, which may exacerbate extrapyramidal symptoms.
• Combination with medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics, due to additive cardiac risk.

Use with caution

• Co‑administration with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase haloperidol levels; dose adjustments may be needed.
• Use with CYP3A4 inducers (e.g., carbamazepine, rifampin) may reduce drug exposure, potentially diminishing therapeutic effect.
• Caution when given with central nervous system depressants (e.g., benzodiazepines, opioids) as combined sedation can be enhanced.